Displayed in English — localised translation pending
blog
Last updated: 2023-03-15

PCA062的臨床實驗資訊

S
Medical Supporter Team
Cross-border medical coordination and editorial review team
PCA062的臨床實驗資訊

PCA062的臨床實驗資訊

PCA062的臨床實驗資訊

Medical Supporter — Information Notice

This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.

Any specific treatment plan must be assessed by a licensed physician in Japan

PCA062的臨床實驗資訊

  • 2016年2月17日
  • 讀畢需時 1 分鐘

主要針對乳癌、食道癌、頭頸癌患者(pCAD陽性),使用 Cadherin抑制藥品(PCA062)進行第一階段臨床試驗。

實施期間 2015.04~2018.06

實施國家:日本、美國、法國、義大利、西班牙

招募志願者人數:75人

以靜脈注射施打PCA062

關於藥品的說明

http://www.cancer.gov/publications/dictionaries/cancer-drug…

諮詢資格:

1.18歲以上

2.確認pCAD發現腫瘤細胞

3.願意進行腫瘤切片檢驗

4.其他的療法無效,腫瘤持續增生

5.可以依照CT檢查腫瘤的狀況

6.PS:2以下

臨床實驗的相關資訊請參考這個網址:

http://www.clinicaltrials.jp/us…/search/directCteDetail.jsp…

===============

注意事項:Medical Supporter翻譯在海外的進行的臨床試驗數據以及醫藥資訊。並非鼓吹諮詢臨床試驗以及各項新藥的使用。若有臨床試驗單位所公佈張貼的連結,可自行聯繫,若是有不清楚如何聯繫可跟我們聯絡。

#頭頸癌 #食道癌

  • 臨床實驗用藥

   (肺癌)Topotecan及Topotecan+Berzosertib治療在第二期臨床試驗結果。   (肺癌)HER2基因變異非小細胞肺癌使用Trastuzumab deruxtecan有效?   (肺癌)抗B7-H3抗體藥物DS-7300有效?

Considering medical care in Japan? Need information and support?

We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free (initial direction only; further services are quoted separately); an advisor will help you clarify the next steps.

Fukuoka HQ: +81-92-984-3200
Formerly officially certified, No. B-066

圖片 1圖片 1

圖片 2圖片 2

圖片 3圖片 3

圖片 4圖片 4

相關癌症資訊

Related Reading